Marrow autotransplantation accelerates haematological recovery in patients with malignant melanoma treated with high-dose melphalan.

In a Phase I study, melphalan 140 mg/m2 was administered to 8 patients with disseminated malignant melanoma. Marrow was removed from the patients immediately before melphalan administration and returned i.v. 8 h later. Studies on marrow culture and melphalan pharmacokinetics predicted that this was...

Descripción completa

Detalles Bibliográficos
Autores principales: McElwain, T. J., Hedley, D. W., Burton, G., Clink, H. M., Gordon, M. Y., Jarman, M., Juttner, C. A., Millar, J. L., Milsted, R. A., Prentice, G., Smith, I. E., Spence, D., Woods, M.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1979
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2009972/
https://www.ncbi.nlm.nih.gov/pubmed/383125

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2009972/
https://www.ncbi.nlm.nih.gov/pubmed/383125

Ejemplares similares